False Negative PAP test? Cytopathologist as a Member of Expert Group in Case of Late Diagnosis of Cervical Cancer
Authors:
J. Dušková
Authors‘ workplace:
Autorka je členkou Komise pro screening karcinomu děložního hrdla Ministerstva zdravotnictví ĆR
; Ústav patologie 1. LF UK a VFN a Katedra patologie IPVZ, Vysoká škola zdravotní, CGOP, Praha, Česká republika
Published in:
Čes.-slov. Patol., 46, 2010, No. 3, p. 62-64
Category:
Original Article
Overview
The Pap test represents a potent tool in reducing the incidence of cervical cancer, though it is unable to eradicate it totally. Under standardized application it has a (very low) failure rate unexpected by the public. In relation to the National screening program of cervical carcinoma an increase in number of litigation cases is to be expected started by women who took part in the screening program and still developed cervical cancer. Together with the international guidelines of Pap test administration and evaluation (Bethesda 2001), widely adopted guidelines for Expert review of histologic slides and Papanicolaou tests in the context of litigation or potential litigation have been formulated (College of American Pathologists 20001).
Arguments for adoption of these guidelines by the Czech Society of Pathologists and their implementation into the National Program of Cervical Cancer Screening are presented.
Sources
1. Fitzgibbons P.L., Austin R.M.: Expert review of histologic slides and Papanicolaou tests in the context of litigation or potential litigation. Surgical Pathology Committee and Cytopathology Committee of the College of American Pathologists. Arch. Pathol. Lab. Med. 124, 2000, 1717–1719.
2. Frable W.J.: Does a zero error standard exist for the Papanicolaou smear? A pathologist’s perspective. Arch. Pathol. Lab. Med. 121, 1997, 301–310.
3. Austin R.M.: College of American Pathologists Conference XXX on quality and liability issues with the Papanicolaou smear: introduction. Arch. Pathol. Lab. Med. 121, 1997, 227–228.
4. Austin R.M.: College of American Pathologists Conference XXX on quality and liability issues with the Papanicolaou smear: summation. Arch. Pathol. Lab. Med. 1997, 121, 341–342. Review.
5. Raab S.S., Grzybicki D.M., Zarbo R.J., Jensen C., Geyer S.J., Janosky J.E., Meier F.A., Vrbin C.M., Carter G., Geisinger K.R.: Frequency and outcome of cervical cancer prevention failures in the United States. Am. J. Clin. Pathol. 2007, 128, 817–824.
6. Sherman M.E., Dasgupta A., Schiffman M., Nayar R., Solomon D.: The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda 2001 System for classifying cervical cytology. Cancer 111, 2007, 15–25.
7. Frable W.J.: Blinded review of Papanicolaou smears. Cancer 2004, 102, 133-135.
8. Austin R.M.: Results of blinded rescreening of Papanicolaou smears versus biased retrospective review. Arch. Pathol. Lab. Med. 1997, 121, 311–4.
9. Frable W.J.: “Litigation cells” in the Papanicolaou smear: extramural review of smears by “experts”. Arch. Pathol. Lab. Med. 1997 121, 292–5.
10. R. Mac De May : The Pap Test. ASCP Press. Chicago , 2005, 250–260
11. Geisinger K.R., Vrbin C., Grzybicki D.M., Wagner P., Garvin A.J., Raab S.S.: Interobserver variability in human papillomavirus test results in cervicovaginal cytologic specimens interpreted as atypical squamous cells. Am. J. Clin. Pathol. 128, 2007, 1010–1014.
12. Kline T.S.: The challenge of quality improvement with the Papanicolaou smear. Arch. Pathol. Lab. Med. 121, 1997, 253–255.
13. Bosch M.M., Rietveld-Scheffers P.E., Boon M.E.: Characteristics of false-negative smears tested in the normal screening situation. Acta Cytol. 36, 1992, 711–716.
14. Austin R.M., Holladay E.B.: Lesson from litigation in: R. Mac De May: The Pap Test. ASCP Press. Chicago , 2005, 250–260
15. Raab S.S., Jones B.A., Souers R., Tworek J.A.: The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. Arch. Pathol. Lab. Med. 132, 2008, 16–22.
16. Dalla Palma P., Giorgi Rossi P., Collina G., Buccoliero A.M., Ghiringhello B., Lestani M., Onnis G., Aldovini D., Galanti G., Casadei G., Aldi M., Gomes V., Giubilato P., Ronco G., NTCC Pathology Group.: The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am. J. Clin. Pathol. 129, 2008, 75–80.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2010 Issue 3
Most read in this issue
- Ovarian Carcinoma: Current Diagnostic Principles
- Autosomal Dominant Polycystic Kidney Disease in the Fetus with Seemingly Negative Family History. A Case Report
- Autoimmune Pancreatitis with Biliary Tree and Liver Involvement as a Part of IgG4-related Autoimmune Sclerosing Disease. Case Report
- False Negative PAP test? Cytopathologist as a Member of Expert Group in Case of Late Diagnosis of Cervical Cancer